Breccia, M., Baccarani, M., Rosti, G., Cottone, F., Cannella, L., Guilhot, F., . . . Efficace, F. (2017). Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients. Health Qual Life Outcomes.
Citação norma ChicagoBreccia, Massimo, Michele Baccarani, Gianantonio Rosti, Francesco Cottone, Laura Cannella, François Guilhot, Marco Vignetti, and Fabio Efficace. "Physicians’ Attitude Towards Selection of Second Line Therapy With Nilotinib and Dasatinib in Chronic Myeloid Leukemia Patients." Health Qual Life Outcomes 2017.
Citação norma MLABreccia, Massimo, et al. "Physicians’ Attitude Towards Selection of Second Line Therapy With Nilotinib and Dasatinib in Chronic Myeloid Leukemia Patients." Health Qual Life Outcomes 2017.